Poseida Therapeutics Revenue and Competitors

Claim your profile

Location

#6094

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Poseida Therapeutics's estimated annual revenue is currently $46.3M per year.(i)
  • Poseida Therapeutics received $30.0M in venture funding in April 2018.
  • Poseida Therapeutics's estimated revenue per employee is $147,596
  • Poseida Therapeutics's total funding is $340.5M.
  • Poseida Therapeutics's current valuation is $328.8M. (January 2022)

Employee Data

  • Poseida Therapeutics has 314 Employees.(i)
  • Poseida Therapeutics grew their employee count by 21% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.7M619%$53MN/A
#2
$34.3M17717%$110MN/A
#3
$0.4M2735%$236.7MN/A
#4
$34.5M178-5%$160MN/A
#5
$3.7M2420%N/AN/A
#6
$147.3M3212%$192.5MN/A
#7
$17.5M113-3%$24.1MN/A
#8
$2.7M4379%N/AN/A
#9
$34.1M220100%N/AN/A
#10
$47.1M304-3%N/AN/A

Poseida Therapeutics is translating best-in-class gene engineering technologies into lifesaving cell therapies. The company is developing CAR T-cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as gene therapies for orphan diseases. P-BCMA-101 is Poseida's lead CAR-T therapy currently in Phase 1 clinical development for the treatment of multiple myeloma. Poseida has assembled a suite of industry-leading gene engineering technologies, including the piggyBac DNA Modification System, TAL-CLOVER and Cas-CLOVER site-specific nucleases, and Footprint-Free Gene Editing (FFGE). For more information, visit www.poseida.com.

keywords:Automotive,Biotechnology,Healthcare,Pharmaceuticals

$340.5M

Total Funding

314

Number of Employees

$46.3M

Revenue (est)

21%

Employee Growth %

$328.8M

Valuation

N/A

Accelerator

Poseida Therapeutics News

2022-04-13 - Chutes & Ladders—Fierce Biotech launches Layoff Tracker ...

Matthew Spear, M.D. is stepping down as chief medical officer of Poseida Therapeutics after almost six years at the company.

2022-04-13 - Next-Gen Partnerships: The Ascent of Advanced Therapies

Under the terms of the deal, which will involve Takeda utilizing Poseida's piggyBac, Cas-CLOVER, biodegradable DNA and RNA nanoparticle...

2022-03-30 - Global Hemophilia A Pipeline Insights | Clinical Trials ...

Through a collaboration, Takeda Pharmaceutical will apply Poseida Therapeutics' technologies to develop up to eight gene therapies including a...

2021-08-30 - Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma

SAN DIEGO, Aug. 30, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the U.S. Food and ...

2021-06-02 - Poseida Therapeutics Announces Virtual 2021 Annual Meeting of Stockholders

SAN DIEGO, June 2, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that its Annual Meeting ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$100.3M316N/AN/A
#2
$15M316-9%N/A
#3
$83.2M31726%N/A
#4
$57.5M3170%N/A
#5
$79.6M3176%N/A

Poseida Therapeutics Funding

DateAmountRoundLead InvestorsReference
2015-12-17$30.0MAMalin Corporation plcArticle
2015-12-29$23.0MUndisclosedArticle
2018-04-05$30.0MBLongitude CapitalArticle